Elevance Health stock trades below analyst fair value as investors weigh second quarter momentum
Published on 08/26/2026 at 22:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health (US2855211023) stock is trading below several published fair value and price target estimates as of August 26, 2026, with investors focusing on the company’s earnings power and valuation gap relative to consensus targets. A recent overview of the shares notes that Elevance Health is valued under a widely cited intrinsic value estimate of $449.10 per share, which is based on long term earnings forecasts rather than short term sentiment, while the stock itself last changed hands at $398.87 in late August 2026 evidence on valuation metrics.
Valuation gap versus analyst targets
Current commentary on Elevance Health highlights that the stock’s $398.87 trading level in August 2026 stands below a most followed fair value estimate of $449.10, implying an upside potential of roughly 13 percent if that estimate is reached valuation comparison detail. In addition, other market data compilations report that the consensus Wall Street target price clusters just under $441 per share, further underscoring that the current quote sits beneath both intrinsic value models and sell side targets consensus target documentation. For investors, the gap between the stock’s recent price in the high $390s and these higher reference points is central to the ongoing valuation debate.
Market data snapshots also put Elevance Health’s market capitalization in the low $60 billion range, with one recent compilation listing the company at $61.847 billion and a price-to-earnings ratio of 8.32 based on current inputs market capitalization overview. Relative to peers in the managed care and health insurance space, that multiple signals that the stock is priced at a single-digit multiple of earnings despite steady revenue and profit growth in recent reporting periods, which contributes to the perception of undervaluation. The combination of a market cap just under $62 billion and a sub-9 price-to-earnings ratio frames Elevance Health as a sizable yet not richly valued player in its sector.
Earnings power and growth expectations
Analyst models summarised in recent coverage suggest that Elevance Health’s long term trajectory depends heavily on incremental revenue gains and margin expansion driven by efficiency initiatives. One detailed valuation exercise assumes that revenue will increase by 1.4 percent annually, from a current base level just under $215 billion in the latest full year, while earnings are expected to rise from $5.0 billion to $7.3 billion over a multi year horizon long term earnings and revenue assumptions. That $2.3 billion modeled increase in earnings underpins the fair value estimate of $449.10 per share, tying Elevance Health’s upside case directly to management’s ability to grow profit faster than revenue.
Within those same projections, Elevance Health’s revenue path is expected to reach approximately $214.8 billion over the forecast period, building on the latest reported revenue base and reflecting incremental contributions from core health insurance operations and adjacent services forecast revenue context. The modeling assumes that value based care arrangements and technology driven efficiency gains help lift margins, enabling earnings growth from $5.0 billion to $7.3 billion even though revenue growth itself is modest. For investors, the key comparison is that earnings would expand by 46 percent in this scenario, compared with low single digit annual revenue growth, a spread that highlights how margin expansion matters more than sheer scale.
Other market data sources reinforce the notion that Elevance Health’s earnings trajectory supports current valuation levels, even as consensus views remain moderately positive rather than exuberant. A widely referenced compilation of analyst opinions classifies the stock as a “Moderate Buy” and reports a consensus target price of $440.90 per share, suggesting that the Street expects gains from the current $398.64 to $404 trading corridor but not a dramatic re-rating consensus rating summary. When measured against the current trading price, that consensus target implies an upside on the order of 10 percent, somewhat less than the upside implied by the $449.10 intrinsic value estimate but still material for long term holders.
Institutional positioning and price performance
Recent regulatory filings and institutional holdings updates show that large investors continue to build or adjust positions in Elevance Health, signaling confidence in the company’s earnings profile. One such filing describes how a global asset manager initiated a sizeable position in the stock, citing the company’s valuation and stable cash flows as key attractions institutional ownership update. Another filing notes additional mid sized allocations from wealth management firms, further diversifying the shareholder base and reinforcing the perception that professional investors view the shares favorably at current levels wealth management position detail.
Price performance metrics compiled in a recent valuation analysis indicate that Elevance Health shares gained 5.61 percent over the trailing 30 day period to the late August 2026 quote of $398.87 and advanced 12.60 percent on a year to date basis short term and year to date performance data. Those gains have brought the stock closer to its consensus price target range, narrowing the gap between current trading and analyst expectations, yet the shares remain below both the $440.90 consensus target and the $449.10 fair value estimate. The combination of a double digit year to date gain and remaining upside to targets contributes to a narrative of steady, rather than explosive, performance.
AI and behavioral health initiatives
A recent in depth analysis underscores that Elevance Health’s strategic initiatives in artificial intelligence and behavioral health services play a central role in its earnings outlook. The piece emphasizes that AI driven efficiency gains in claims processing, network management, and care coordination are expected to reduce administrative costs and improve margins over time discussion of AI and behavioral health strategy. In parallel, investments in behavioral health offerings aim to address rising demand for mental health services, potentially expanding revenue in this segment and strengthening Elevance Health’s overall product mix.
Under the modeled scenario, these AI and behavioral health initiatives are expected to support the path from $5.0 billion in current earnings to $7.3 billion over the forecast period, even as revenue grows by only 1.4 percent annually from a base that is already in the $210 billion range link between initiatives and earnings growth. The analysis notes that, if these initiatives succeed, Elevance Health’s fair value estimate of $449.10 per share could be reached without assuming aggressive revenue expansion, because the earnings contribution of efficiency gains would be significant. For investors, the central comparison is between this modeled path and more conservative scenarios in which margins remain flat and earnings growth slows, which would justify a smaller valuation gap.
Managed care sector comparison
Sector level commentary comparing Elevance Health with other managed care stocks suggests that the company sits within a group of large insurers facing both opportunities and headwinds in the broader health care marketplace. A recent comparative analysis between Elevance Health and another leading managed care company concludes that the peer may have slightly stronger earnings momentum and a more favorable risk reward profile at current prices, yet Elevance Health still benefits from solid fundamentals and exposure to long term health care demand trends sector comparison analysis. In that context, Elevance Health’s valuation metrics, including an 8.32 price-to-earnings ratio and an implied fair value of $449.10 per share, are key differentiators.
When comparing price performance, Elevance Health’s 12.60 percent gain in 2026 to date sits alongside peers that have also delivered double digit returns, though some have seen larger swings due to company specific catalysts sector return context. The stock’s 5.61 percent gain over the past month has reduced discount levels relative to fair value models, yet the shares continue to trade at a valuation that many models regard as modest for a company of its size and earnings power. For investors assessing the sector, this places Elevance Health in the category of steady performers with room for further upside if earnings deliver as expected.
Flagship health insurance offerings
Beyond the numbers, Elevance Health’s core business revolves around health insurance plans offered through its branded health benefits and health services operations. The company provides a range of commercial, Medicaid, and Medicare plans that cover medical, pharmacy, and specialty services across multiple US states, often under well known Blue Cross and Blue Shield brands. These plans form the backbone of Elevance Health’s revenue, contributing to the more than $200 billion revenue base used in recent valuation models and supporting the earnings forecasts out to the mid 2020s.
Elevance Health has also been expanding its portfolio of value based care arrangements, in which provider reimbursements are linked to patient outcomes rather than volume of services. These arrangements, combined with digital tools for members and providers, are intended to improve care coordination and reduce unnecessary costs, thereby supporting the margin expansion that underlies the $2.3 billion projected increase in earnings from $5.0 billion to $7.3 billion. As these offerings evolve, they are expected to play a larger role in both revenue mix and profitability.
Elevance Health stock and latest trading context
Recent market snapshots place Elevance Health stock at $398.87 as of August 26, 2026, with that level reflecting a 5.61 percent gain over the prior 30 days and a 12.60 percent gain year to date current trading and performance snapshot. Those gains have brought the shares closer to a consensus target price of $440.90 and a widely referenced fair value estimate of $449.10, yet the stock still trades at a discount to both, leaving potential upside if earnings and margin expansion materialize as projected. With a market capitalization reported at $61.847 billion and a price-to-earnings ratio of 8.32 in recent data compilations, Elevance Health remains a major player in US managed care with valuation metrics that many investors view as undemanding.
Read more
Digital health and care management
Elevance Health’s digital health and care management solutions form a key part of its strategy to improve outcomes and reduce costs. Through mobile apps, online portals, and data driven care management platforms, the company supports members in finding in network providers, managing prescriptions, monitoring chronic conditions, and accessing telehealth services. These tools are integrated with claims data and clinical information to help identify patients who may benefit from early interventions, which can reduce hospitalizations and improve long term health outcomes.
By combining these digital offerings with traditional health insurance plans, Elevance Health aims to deepen engagement with members and create a more coordinated care experience. The company’s investments in digital infrastructure are also designed to support the AI driven efficiency gains highlighted in recent valuation analyses, as automated workflows and predictive analytics rely on robust data pipelines and user friendly interfaces. As adoption increases, these digital tools could contribute both to higher member satisfaction and to the margin expansion that underpins Elevance Health’s fair value estimates.
Shares and valuation outlook
Based on recent market data as of August 26, 2026, Elevance Health shares trade on the New York Stock Exchange at $398.87, denominated in US dollars, with a reported market capitalization of $61.847 billion and a price-to-earnings ratio of 8.32 latest valuation snapshot. The shares have delivered a 12.60 percent gain since the start of 2026 and a 5.61 percent increase over the past month, while still sitting below a consensus target price of $440.90 and an intrinsic value estimate of $449.10 that is built on earnings growth from $5.0 billion to $7.3 billion over the forecast period. For investors, the interplay between this valuation gap, the company’s AI and behavioral health initiatives, and the broader managed care landscape will shape how Elevance Health stock trades in the coming quarters.
Company facts
Company: Elevance Health, Inc.
ISIN: US2855211023
Ticker: ELV
Exchange: New York Stock Exchange (NYSE)
Price (as of August 26, 2026, 11:06 a.m. ET): $398.87 USD
Market cap: $61.847 billion (as of August 26, 2026)
Sector / Industry: Health Care / Managed Health Care
Index membership: S&P 500
